A Phase 1b Study of GDC-0449 Following Autologous Transplantation in Patients With High Risk First Remission or Relapsed Multiple Myeloma

Trial Profile

A Phase 1b Study of GDC-0449 Following Autologous Transplantation in Patients With High Risk First Remission or Relapsed Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2014

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2013 Planned End Date changed from 1 Mar 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Feb 2013 Planned number of patients changed from 35 to 38 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top